In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy
Novo Nordisk blames middlemen in U.S. healthcare system for high prices of weight loss drugs Wegovy and Ozempic
Read Next
- SFC issues notices to Interactive Brokers, SBI, Monmonkey, Soochow to freeze certain client accounts
- Private consumption driving growth in Q3 with rural India taking lead: RBI, ET BFSI
- Nvidia (NVDA) stock slumps despite Q3 earnings beat
- India’s consumer durable makers to log 11-12 pc growth in FY25, ET BFSI
- Binance Offers NOTCOIN Red Packet Giveaway via Binance Pay
- Snowflake (SNOW) Q3 earnings report 2025
- India’s export outlook brighter as manufactured goods gain share: RBI, ET BFSI
